Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6855
Abstract: Background ABP 501 is the first approved biosimilar to adalimumab. Patient withdrawals from clinical trials can result in missing data, which may lead to loss of statistical power and bias of the treatment difference estimate.…
read more here.
Keywords:
amgen inc;
tipping point;
point sensitivity;
abp 501 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1354.1354
Abstract: Acute myeloid leukemia (AML) is a disease with high unmet medical need. Standard induction chemotherapy can lead to complete remission in patients with a favorable genetic risk profile; however, about half of patients are ineligible…
read more here.
Keywords:
amgen inc;
research;
bite;
flt3 ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Diabetes"
DOI: 10.2337/db18-128-or
Abstract: Aim: To examine the efficacy of 12 weeks of monthly evolocumab (EvoMab) 420 mg vs. placebo (Pbo) in lowering LDL-C in those with type 2 diabetes mellitus (T2DM) and hypercholesterolemia or mixed dyslipidemia and on…
read more here.
Keywords:
amgen inc;
support self;
research support;
Sign Up to like & get
recommendations!
0
Published in 2019 at "Diabetes"
DOI: 10.2337/db19-327-or
Abstract: Lifestyle interventions have shown to reverse hyperglycemia to normoglycemia. However, most interventions are cost-intensive. Formula diets have shown to improve glycemic control and be cost-effective. We, therefore, hypothesized that adding a low-carbohydrate formula diet to…
read more here.
Keywords:
amgen inc;
lifestyle intervention;
formula diet;
low carbohydrate ... See more keywords